Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations provide only read-only, open-world, and idempotent hints. The description goes far beyond that: it discloses internal cascading lookups, graceful degradation when GLEIF/OpenFIGI are unavailable, explicit `unresolved` fields, source-labelled identifiers, ambiguity handling via `figi_candidates`, and behavior for non-equity instruments. This is a strong behavioral disclosure.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is information-dense and front-loaded with example query phrases, but it is a long, unwieldy single block of text with many nested parentheticals. Every sentence carries useful content, yet structure is sacrificed: scannability would improve dramatically with bullets or clear separation of types, inputs, and return behavior.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema and moderate parameter count, the description is very complete: it covers accepted inputs, return identifiers, source attribution, unresolved results, ambiguity policy, degradation behavior, supported entity types, and even non-US issuer coverage. An agent has enough grounding to select and invoke the tool correctly across a wide range of queries.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the schema carries the baseline parameter documentation. The description adds meaningful context: accepted input forms (ticker, CIK, ISIN, name for company; brand/generic for drug), the requirement to pass only the entity name rather than the full noun phrase, and how ISIN inputs resolve to legal entities. This enriches rather than merely repeats the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific action — resolving a user-spoken name to canonical/official identifiers — and names concrete outputs (CIK, ticker, LEI, FIGI, RxCUI). It clearly differentiates the tool from siblings like entity_profile or search_within by explicitly saying to use it when you have a name but need an ID.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'Use FIRST whenever you have a name but need an ID', enumerates supported entity types, and explains behavior when resolution is ambiguous. It does not explicitly name alternative sibling tools or state when not to use it, so it falls just short of full 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation3/5

Several tools form overlapping families (ask_pipeworx/ask_pipeworx_beta/ask_pipeworx_grounded/deep_research, plus the six polymarket_* tools), and ask_pipeworx_beta is currently an exact behavioral duplicate. The long descriptions usually disambiguate them, but an agent could still struggle to quickly choose between similar research and edge-detection tools.

Naming Consistency3/5

Names are uniformly snake_case and prefix families like pipeworx_* and polymarket_* help, but there is no consistent verb_noun pattern: subjects, table_meta, recent_alerts, and entity_profile are noun phrases while remember, generate_llms_txt, and compare_entities are action-first. The mixed conventions are readable but less predictable than a uniform pattern.

Tool Count2/5

34 tools is well into the 'too many' range for a single tool set, even if each is individually documented. Several could plausibly be consolidated, such as ask_pipeworx_beta, the polymarket edge tools, and the AI-visibility pair.

Completeness4/5

For its broad stated purpose, the set covers the full lifecycle: lookup/research, entity profiles, comparisons, claim validation, prediction-market edge analysis, memory, subscriptions, and discovery. Minor gaps exist, such as no direct fetch-by-URI tool or subscription update path, but most workflows have a clear route.